Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

YSG vs ZEPP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

YSG Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

YSG Overall Winner 6-Pillar Tally: YSG 4 – 1 ZEPP (1 Tie) Matrix Metrics: YSG 5 – 4 ZEPP

As of Nov 20, 2026, Yatsen Holding Limited (YSG) is the stronger overall head-to-head candidate over Zepp Health Corporation (ZEPP) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). YSG carries a Unified Composite Score of 36.0/100 (SELL) at $1.58 (1.4x Forward P/E, -6.3% operating margin), whereas ZEPP carries 45.7/100 (HOLD) at $2.31 (3.1x Forward P/E, -12.6% operating margin).

  • Composite vs. Pillar Nuance: While ZEPP currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. YSG 36.0/100 SELL), YSG captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. -12.6% operating margin) and revenue trajectory (+5.1% vs. +6.9% YoY).
  • Technical & Structure Timing Caution: YSG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.6); meanwhile ZEPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About YSG vs ZEPP
YSG NYSE Head-to-Head Winner
Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares
Perfumes, Cosmetics & Other Toilet Preparations
$1.58
-17.28% 1D
Market Cap $179.2M
TTM Revenue $4.54B
Forward P/E 1.4x
Beta / 30D Vol 1.66β · 105% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 25.0 Fund 60.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.5%), weak momentum, RSI 29
RSI-14: 28.6 · SMA20: $2.02 · SMA50: $2.35
ZEPP NYSE
Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares
Electronic Computers
$2.31
-8.33% 1D
Market Cap $37.0M
TTM Revenue $276M
Forward P/E 3.1x
Beta / 30D Vol 2.12β · 68% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 63.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.0%), weak momentum, RSI 35
RSI-14: 35.4 · SMA20: $2.40 · SMA50: $3.21

6-Pillar Scorecard Institutional Category Breakdown (YSG 4 – 1 ZEPP)

Columns: Metric · YSG · ZEPP
1. Valuation Multiples ZEPP
Forward P/E 1.4x 3.1x
Trailing P/E N/M 3.1x
PEG Ratio N/M N/M
EV / Revenue N/M 0.1x
2. Growth & Scale YSG
Revenue Growth (YoY) +5.1% +6.9%
Earnings Growth (YoY) +0.0% -68.1%
TTM Revenue (USD) $4.54B $276M
Market Cap $179.2M $37.0M
3. Profitability & Quality YSG
Gross Margin 77.4% 38.6%
Operating Margin -6.3% -12.6%
Net Profit Margin -4.6% -15.8%
Return on Equity (ROE) -7.6% -21.2%
4. Balance Sheet & Cash Flow YSG
Cash Generation (TTM) -$231M EBITDA -$30M EBITDA
Cash Flow Margin -5.1% EBITDA Mgn -11.0% EBITDA Mgn
Net Cash / Leverage $4.26 Book/Sh · -7.6% ROE $11.68 Book/Sh · -21.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 725.4% (50th %ile) 124.3% (94th %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat YSG
OpEx & R&D Intensity 83.7% of Rev ($3.80B) 51.2% of Rev ($141M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Consumer Electronics Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: YSG (5) vs ZEPP (4)
Institutional Metric YSG ZEPP Criterion Row Edge
Market Capitalization
Scale
$179.2M $37.0M Larger Scale YSG
Trailing P/E Ratio
Valuation
N/M 3.1x Lower Multiple ZEPP
Forward P/E Ratio
Valuation
1.4x 3.1x Lower Multiple YSG
Revenue Growth (YoY)
Growth
+5.1% +6.9% Higher Growth ZEPP
Operating Margin (TTM)
Profitability
-6.3% -12.6% Higher Margin YSG
Net Profit Margin
Profitability
-4.6% -15.8% Higher Margin YSG
Return on Equity (ROE)
Capital Efficiency
-7.6% -21.2% Higher ROE YSG
52-Week Range Position
Momentum
0% ($2–$7) 0% ($2–$33) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.66β · 105% Vol 2.12β · 68% Vol Lower Realized Risk ZEPP
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 45.7 / 100 (HOLD) Higher Composite ZEPP
Trailing 12M Revenue (USD)
Operating Scale
$4.54B $276M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.4% 38.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$231M EBITDA ($4.26 Book/Sh · -7.6% ROE) -$30M EBITDA ($11.68 Book/Sh · -21.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZEPP +21.55 pp
YSG: -34.71% · ZEPP: -13.16%
3M Horizon YSG +6.38 pp
YSG: -47.33% · ZEPP: -53.71%
6M Horizon YSG +34.2 pp
YSG: -39.0% · ZEPP: -73.2%
1Y Horizon YSG +16.94 pp
YSG: -73.45% · ZEPP: -90.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on YSG vs ZEPP. Trailing 12-month operating profitability (YSG -6.3% vs ZEPP -12.6%) and valuation multiples (YSG 1.4x vs ZEPP 3.1x Forward P/E) are benchmarked directly in Pillar 4 below.

YSG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.54B
Gross Margin77.4%
Op. Margin-6.3%
ROE / Fwd P/E-7.6% · 1.4x
ZEPP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$276M
Gross Margin38.6%
Op. Margin-12.6%
ROE / Fwd P/E-21.2% · 3.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
YSG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 725.4%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YSG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZEPP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.3%
IV Percentile 94th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZEPP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
YSG Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $179.2M market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment 83.7% of Rev ($3.80B)
90D Engineering Disclosures 0 Published
ZEPP Moat Profile Cyclical / Execution-Driven Positioning
Consumer Electronics Operator
Competes within the Consumer Electronics value chain with $37.0M market capitalization and -12.6% operating margin.
OpEx & R&D Reinvestment 51.2% of Rev ($141M)
90D Engineering Disclosures 0 Published

Investor FAQ YSG vs ZEPP Key Questions & Quantitative Answers

As of Nov 20, 2026, Yatsen Holding Limited (YSG) is the stronger overall head-to-head candidate over Zepp Health Corporation (ZEPP) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). YSG carries a Unified Composite Score of 36.0/100 (SELL) at $1.58 (1.4x Forward P/E, -6.3% operating margin), whereas ZEPP carries 45.7/100 (HOLD) at $2.31 (3.1x Forward P/E, -12.6% operating margin). Composite vs. Pillar Nuance: While ZEPP currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. YSG 36.0/100 SELL), YSG captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6.3% vs. -12.6% operating margin) and revenue trajectory (+5.1% vs. +6.9% YoY). Technical & Structure Timing Caution: YSG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.6); meanwhile ZEPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

YSG leads the Growth & Scale pillar: YSG posts +5.1% YoY revenue growth and +0.0% YoY earnings growth on $4.54B TTM revenue (77.4% gross margin, -6.3% operating margin), compared with ZEPP at +6.9% YoY revenue growth and -68.1% YoY earnings growth on $276M TTM revenue (38.6% gross margin, -12.6% operating margin). On trailing 12-month operating scale, YSG generates $4.54B in USD-normalized revenue versus $276M for ZEPP. In operating R&D and SG&A reinvestment, YSG deploys 83.7% of Rev ($3.80B) (0 90-day corporate R&D disclosures) versus 51.2% of Rev ($141M) (0 disclosures) for ZEPP.

ZEPP screens cheaper on headline valuation multiples. YSG trades at 1.4x Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-5.1% EBITDA margin), whereas ZEPP trades at 3.1x Forward P/E, 3.1x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-11.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against YSG (-7.6% ROE) versus ZEPP (-21.2% ROE) capital efficiency.

In options market volatility and institutional positioning, YSG carries 725.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 105% Vol realized risk). By comparison, ZEPP carries 124.3% implied volatility (94th %ile, Extreme (>80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.12β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares (YSG) Research Suite

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares (ZEPP) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.